Your browser doesn't support javascript.
loading
Advanced Heart Failure Therapies for Hypertrophic Cardiomyopathy: State-of-the-Art Review and an Updated Analysis From UNOS.
Liang, Lusha W; Lumish, Heidi S; Sewanan, Lorenzo R; Shimada, Yuichi J; Maurer, Mathew S; Weiner, Shepard D; Sayer, Gabriel; Uriel, Nir; Clerkin, Kevin J.
Afiliação
  • Liang LW; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Lumish HS; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Sewanan LR; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Shimada YJ; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Maurer MS; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Weiner SD; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Sayer G; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Uriel N; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Clerkin KJ; Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA. Electronic address: kjc2142@cumc.columbia.edu.
JACC Heart Fail ; 11(11): 1473-1480, 2023 11.
Article em En | MEDLINE | ID: mdl-37632495
ABSTRACT
Hypertrophic cardiomyopathy (HCM) is most commonly associated with obstructive symptoms and sudden cardiac death; however, predominantly nonobstructive advanced heart failure in HCM, marked by medically refractory disease with severe functional impairment, occurs in 5% to 7% of patients with HCM. The diagnosis relies on the integration of imaging (echocardiography/cardiac magnetic resonance), hemodynamic data, and cardiopulmonary exercise testing to identify the patients who will benefit from advanced heart failure therapies. Most advanced heart failure therapies focus on systolic dysfunction and are not always applicable to this patient population. Left ventricular assist devices may be an option in a highly selected population with left ventricular dilation. Heart transplantation is often the best option for patients with advanced heart failure in HCM with excellent post-transplantation survival.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiomiopatia Hipertrófica / Transplante de Coração / Insuficiência Cardíaca Limite: Humans Idioma: En Revista: JACC Heart Fail Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cardiomiopatia Hipertrófica / Transplante de Coração / Insuficiência Cardíaca Limite: Humans Idioma: En Revista: JACC Heart Fail Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos